Significance of GPRC5D as a Target for R/R MM

Subgroup data from the IMROZ trial showed Isa-VRd improved survival and responses vs VRd alone in patients who were frail with newly diagnosed myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.